GL

Gaurav Lalchandra Haral

Active Director Director DIN 10531747
DIN 10531747 First appointment Mar 2024 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Gaurav Lalchandra Haral

Data last updated:

Gaurav Lalchandra Haral is a Director at Beatris Pharma Private Limited (since 2024). The company operates in Paper.

DIN 10531747
Primary Designation Director
Industry Paper
First Appointment 01 Mar 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Beatris Pharma Private Limited U21001PN2024PTC228757
Director01 Mar 20242024Active

Directorship timeline

Open interactive timeline →
Beatris Pharma Private Limited
Premium access

Shareholding and investment profile for Gaurav Lalchandra Haral

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gaurav Lalchandra Haral

Gaurav Lalchandra Haral currently holds 1 directorship: Beatris Pharma Private Limited (Director, since 01 Mar 2024).

Gaurav Lalchandra Haral was first appointed on 01 Mar 2024 as Director at Beatris Pharma Private Limited.

The current boards of Gaurav Lalchandra Haral's companies include Atulkumar Babasaheb Bande (Beatris Pharma Private Limited), Nagesh Pandurang Rohokale (Beatris Pharma Private Limited), Renuka Babasaheb Modhave (Beatris Pharma Private Limited), Swara Mahesh Zanjad (Beatris Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available